Compare AMPH & GSBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMPH | GSBD |
|---|---|---|
| Founded | 1996 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 971.8M | 1.0B |
| IPO Year | 2005 | 2013 |
| Metric | AMPH | GSBD |
|---|---|---|
| Price | $18.18 | $8.89 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 8 | 2 |
| Target Price | ★ $28.38 | $9.00 |
| AVG Volume (30 Days) | 644.5K | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 13.49% |
| EPS Growth | N/A | ★ 87.27 |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $719,887,000.00 | N/A |
| Revenue This Year | $6.90 | N/A |
| Revenue Next Year | $4.64 | N/A |
| P/E Ratio | $130.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.65 | $8.65 |
| 52 Week High | $31.26 | $12.03 |
| Indicator | AMPH | GSBD |
|---|---|---|
| Relative Strength Index (RSI) | 40.00 | 37.39 |
| Support Level | $17.03 | N/A |
| Resistance Level | $20.08 | $10.13 |
| Average True Range (ATR) | 0.81 | 0.22 |
| MACD | -0.21 | -0.08 |
| Stochastic Oscillator | 19.16 | 14.71 |
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests in U.S. middle-market companies such as banks and the public debt markets. The company focuses on the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.